Can HER2-Positive Breast Cancer come back after 5 years of remission

Can HER2-Positive Breast Cancer Return After 5 Years of Remission?

Yes, HER2-positive breast cancer can recur even after 5 years of remission, though the risk decreases significantly over time. Let me explain what the evidence shows and what this means for you.

Understanding Recurrence Risk Over Time

The good news: HER2-positive breast cancer has one of the better prognoses among breast cancer types, especially with modern anti-HER2 therapies like trastuzumab (Herceptin) and pertuzumab (Perjeta).

The realistic picture: While most recurrences happen in the first 2-3 years after treatment, late recurrences (after 5+ years) do occur, though they're less common. The longer you remain disease-free, the lower your ongoing risk becomes—but it never reaches zero.

What the Research Shows

According to research presented in the CancerPatientLab webinars on proteomics and HER2 treatment, patients with very high HER2 expression who received anti-HER2 therapy showed no events at all over 6-7 years of follow-up. This demonstrates that optimal HER2-targeted treatment can provide durable, long-term control.

However, this doesn't mean recurrence is impossible. The key factors that influence your individual risk include:

• How well your cancer responded initially to treatment
• Your specific HER2 expression level (higher expression generally responds better to anti-HER2 drugs)
• Whether you completed recommended adjuvant (post-surgery) therapy
• Hormone receptor status (if your cancer is also ER/PR positive, this affects recurrence patterns)
• Stage at diagnosis

Why Late Recurrence Can Happen

Cancer cells can sometimes:

• Develop resistance to treatments over time
• Remain dormant (inactive) for years before reactivating
• Evolve new mutations that allow them to escape immune surveillance

This is why ongoing monitoring remains important even years after treatment.

What You Should Do

Questions to ask your oncologist:

1. What is MY specific recurrence risk based on my tumor characteristics, stage, and treatment response?
2. What surveillance schedule do you recommend? (imaging, blood work, clinical exams)
3. Are there any new biomarkers or tests that could help detect recurrence earlier if it were to happen?
4. If recurrence did occur, what treatment options would be available? (This is important to know—modern options for HER2+ recurrent disease have improved significantly)
5. Should I consider any maintenance therapy or extended treatment beyond standard recommendations?

The Bigger Picture

The fact that you've reached 5 years of remission is genuinely significant and reflects the success of modern HER2-targeted therapy. The medical community has made remarkable progress in treating HER2-positive breast cancer over the past two decades. According to the webinar discussions on HER2 proteomics, anti-HER2 strategies have fundamentally changed outcomes for patients with this diagnosis.

That said, cancer surveillance is a lifelong process. Regular follow-up with your oncology team—even years after treatment—helps catch any recurrence as early as possible, when treatment options are typically most effective.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.